Condor Capital Management’s Novavax NVAX Stock Holding History

Condor Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-639	Closed	-$15K	–	171
2017 Q3	$15K	Hold	639	–	–	﹤0.01%	174
2017 Q2	$15K	Buy	+639	New	+$12.5K	﹤0.01%	177

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Condor Capital Management's NVAX Position: Q4 2017 in Review

Condor Capital Management sold out of Novavax (NVAX) in Q4 2017, closing a stake of 639 shares — an estimated $15K sold.

Condor Capital Management first reported a position in NVAX in Q2 2017 and held it in 2 quarters. The position peaked at $15K in Q3 2017. 134 funds tracked by Wall St. Rank hold NVAX as of Q4 2017.

Condor Capital Management reported no remaining Novavax position as of Q4 2017 after selling out during the quarter.
Condor Capital Management sold 639 Novavax shares in Q4 2017, an estimated $15K.
Condor Capital Management first reported a position in Novavax in Q2 2017 and held it in 2 quarters.
Condor Capital Management's Novavax position peaked at $15K in Q3 2017.
134 funds tracked by Wall St. Rank held Novavax as of Q4 2017.

Based on Condor Capital Management's 13F filing for Q4 2017, filed 8 Feb 2018.